Literature DB >> 17473188

Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2.

Marc R J Carlson1, Whitney B Pope, Steve Horvath, Jerome G Braunstein, Phioanh Nghiemphu, Cho-Lea Tso, Ingo Mellinghoff, Albert Lai, Linda M Liau, Paul S Mischel, Jun Dong, Stanley F Nelson, Timothy F Cloughesy.   

Abstract

PURPOSE: Vascular endothelial growth factor (VEGF) is a potent mediator of vascular permeability. VEGF inhibition reduces edema and tumor burden in some patients with malignant glioma, whereas others show no response. The role of VEGF expression in edema production and the relationship to survival is not well understood. EXPERIMENTAL
DESIGN: Using DNA microarray analysis, we examined VEGF and related gene expression in 71 newly diagnosed malignant gliomas and analyzed the relationship to edema and survival. RESULTS AND
CONCLUSIONS: VEGF expression was predictive of survival in tumors with little or no edema [Cox proportional hazard model, 6.88; 95% confidence interval (95% CI), 2.61-18.1; P<0.0001], but not in tumors with extensive edema. The expression of several proangiogenic genes, including adrenomedullin (correlation coefficient, 0.80), hypoxia-inducible factor-1A (0.51), and angiopoietin-2 (0.44), was correlated with VEGF expression (all with P<0.0001), whereas that of several antiangiogenic genes was inversely correlated. The expression of six genes was increased greater than 3-fold in edematous versus nonedematous tumors in the absence of increased VEGF expression. The most increased, neuronal pentraxin 2 (NPTX2, 7-fold change), was predictive of survival in tumors with the highest levels of edema, in contrast to VEGF (hazard ratio, 2.73; 95% CI, 1.49-5.02; P=0.049). NPTX2 was tightly correlated with expression of the water channel aquaporin-3 (0.74, P<0.0001). These results suggest that there are both VEGF-dependent and VEGF-independent pathways of edema production in gliomas and may explain why edema is not reduced in some patients following anti-VEGF treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473188     DOI: 10.1158/1078-0432.CCR-06-2772

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  55 in total

1.  MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.

Authors:  K Yamashita; A Hiwatashi; O Togao; K Kikuchi; R Hatae; K Yoshimoto; M Mizoguchi; S O Suzuki; T Yoshiura; H Honda
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-24       Impact factor: 3.825

2.  Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.

Authors:  Patrizia Farina; Emeline Tabouret; Pierre Lehmann; Maryline Barrie; Gregorio Petrirena; Chantal Campello; Celine Boucard; Thomas Graillon; Nadine Girard; Olivier Chinot
Journal:  J Neurooncol       Date:  2017-03-06       Impact factor: 4.130

Review 3.  Antiangiogenic strategies for treatment of malignant gliomas.

Authors:  Andrew S Chi; Andrew D Norden; Patrick Y Wen
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

4.  Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study.

Authors:  Nicholas Czarnek; Kal Clark; Katherine B Peters; Maciej A Mazurowski
Journal:  J Neurooncol       Date:  2017-01-10       Impact factor: 4.130

5.  Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival.

Authors:  W B Pope; L Mirsadraei; A Lai; A Eskin; J Qiao; H J Kim; B Ellingson; P L Nghiemphu; S Kharbanda; R H Soriano; S F Nelson; W Yong; H S Phillips; T F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

Review 6.  Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.

Authors:  G Thompson; S J Mills; D J Coope; J P B O'Connor; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 7.  Conventional MRI evaluation of gliomas.

Authors:  N Upadhyay; A D Waldman
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 8.  Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.

Authors:  Joost J C Verhoeff; Olaf van Tellingen; An Claes; Lukas J A Stalpers; Myra E van Linde; Dirk J Richel; William P J Leenders; Wouter R van Furth
Journal:  BMC Cancer       Date:  2009-12-16       Impact factor: 4.430

9.  Time course of imaging changes of GBM during extended bevacizumab treatment.

Authors:  Suchitra Ananthnarayan; Jennie Bahng; James Roring; Phioanh Nghiemphu; Albert Lai; Timothy Cloughesy; Whitney B Pope
Journal:  J Neurooncol       Date:  2008-04-04       Impact factor: 4.130

10.  Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images.

Authors:  Kourosh M Naeini; Whitney B Pope; Timothy F Cloughesy; Robert J Harris; Albert Lai; Ascia Eskin; Reshmi Chowdhury; Heidi S Phillips; Phioanh L Nghiemphu; Yalda Behbahanian; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2013-02-26       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.